<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28389">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737150</url>
  </required_header>
  <id_info>
    <org_study_id>15-292</org_study_id>
    <nct_id>NCT02737150</nct_id>
  </id_info>
  <brief_title>SecOnd-generation seLf-expandable Versus Balloon-expandable Valves and gEneral Versus Local Anesthesia in TAVI</brief_title>
  <acronym>SOLVE-TAV</acronym>
  <official_title>CompariSon of secOnd-generation seLf-expandable Versus Balloon-expandable Valves and gEneral Versus Local Anesthesia in Transcatheter Aortic Valve Implantation (SOLVE-TAVI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Giessen and Marburg, Campus Giessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart Center Leipzig, University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Schleswig-Holstein, Campus Kiel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum der Stadt Ludwigshafen am Rhein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Links der Weser Bremen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Schleswig-Holstein, Campus Lübeck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Luebeck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to demonstrate equivalence of second-generation self-expandable valves
      (CoreValve Evolut R) in comparison to second-generation balloon-expandable valves (Edwards
      Sapien 3) and of local anesthesia with conscious sedation in comparison to general
      anesthesia with respect to safety and efficacy in high-risk patients with severe aortic
      stenosis undergoing transcatheter aortic valve implantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Device)</measure>
    <time_frame>30 day follow-up</time_frame>
    <description>Number of participants with adverse events related to the treatment at 30-day follow-up consisting of all-cause mortality, stroke, moderate or severe prosthetic valve regurgitation, and permanent pacemaker implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Anesthesia)</measure>
    <time_frame>30 day follow-up</time_frame>
    <description>Number of participants with adverse events related to the treatment at 30-day follow-up consisting of all-cause mortality, stroke, myocardial infarction, infection requiring antibiotic treatment, and acute kidney injury</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">444</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Self-expandable valve under local anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CoreValve Evolut R valve under local anesthesia with conscious sedation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Self-expandable valve under general anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CoreValve Evolut R valve under general anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Balloon-expandable valve under local anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Edwards Sapien 3 valve under local anesthesia with conscious sedation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Balloon-expandable valve under general anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Edwards Sapien 3 valve under under general anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CoreValve Evolut R</intervention_name>
    <arm_group_label>Self-expandable valve under local anesthesia</arm_group_label>
    <arm_group_label>Self-expandable valve under general anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards Sapien 3</intervention_name>
    <arm_group_label>Balloon-expandable valve under local anesthesia</arm_group_label>
    <arm_group_label>Balloon-expandable valve under general anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local anesthesia with conscious sedation</intervention_name>
    <arm_group_label>Self-expandable valve under local anesthesia</arm_group_label>
    <arm_group_label>Balloon-expandable valve under local anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>General anesthesia</intervention_name>
    <arm_group_label>Self-expandable valve under general anesthesia</arm_group_label>
    <arm_group_label>Balloon-expandable valve under general anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe symptomatic aortic valve stenosis defined as aortic valve area (AVA) ≤ 1cm2 or
             0.6 cm²/m²

          -  Age ≥75 years and/or logistic European System for Cardiac Operative Risk Evaluation
             (EuroSCORE) ≥20% and/or Society of Thoracic Surgeons (STS) risk score ≥10% and/or
             high risk/contraindication to conventional surgical aortic valve replacement

          -  Native aortic valve annulus measuring 18-29 mm

          -  Suitability for transfemoral vascular access

          -  Written informed consent

        Exclusion Criteria:

          -  Life expectancy &lt;12 months due to comorbidities

          -  Cardiogenic shock or hemodynamic instability

          -  History of or active endocarditis

          -  Contraindications for transfemoral access

          -  Active peptic ulcer or upper gastro-intestinal bleeding &lt;3 months

          -  Hypersensitivity or contraindication to aspirin, heparin or clopidogrel

          -  Contraindication for a specific mode of anesthesia as judged by the cardiac
             anesthesia representative of the Heart Team

          -  Active infection requiring antibiotic treatment

          -  Participation in another trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Thiele</last_name>
      <email>holger.thiele@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Holger Thiele</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 24, 2016</lastchanged_date>
  <firstreceived_date>April 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Luebeck</investigator_affiliation>
    <investigator_full_name>Holger Thiele</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
